ElitePhysiqMD review

What it is

ElitePhysiqMD is a physician-led telehealth platform, launched in late 2025 and now trading at myepmd.com, that sells peptide therapy, hormone therapy, GLP-1 weight-loss medication, ED treatment, hair restoration and lab testing from a single storefront. Its peptide shelf is unusually explicit: BPC-157 and BPC-157+TB500 under recovery, sermorelin, CJC-1295/ipamorelin, tesamorelin and tesamorelin/ipamorelin under growth hormone, NAD⁺, MOTS-C, epithalon, GHK-Cu and glutathione under longevity, PT-141 and kisspeptin under sexual health, plus thymosin alpha-1, low-dose naltrexone and B12. It states LegitScript certification, HIPAA compliance, HSA/FSA eligibility, dispensing from state-licensed 503A and 503B compounding pharmacies, and new patients in all 50 states.

How it works

Asynchronous and storefront-shaped. You pick a product, complete a short online assessment, a board-certified physician reviews whether treatment is appropriate, and medication ships in a stated five to seven business days in discreet packaging. There is no video call in the default path. That is convenient and it is also the trade: a growth-hormone-axis peptide bought from a product grid, with no lab work described anywhere in the flow, is a purchase where the clinical conversation you would want is the part being optimised away. Two structural details are worth carrying into any decision. First, the platform names its dispensing model — state-licensed 503A and 503B compounding pharmacies registered with FDA — but names no individual pharmacy, and no medical director is identified anywhere on the site. Second, the company is young: its own site metadata dates the platform to late 2025, which means there is essentially no independent operating history to weigh. Cancellation is stated plainly as anytime with no penalties or fees, and first-order shipping is free via an auto-applied code, with ongoing shipping cost undisclosed.

Pricing transparency

Published, per molecule, on the shelf — which is the whole reason this entry exists. The subscription prices are sermorelin $267.30 a month, CJC-1295/ipamorelin $315, tesamorelin $274.50, tesamorelin/ipamorelin $274.50, BPC-157 $225, BPC-157+TB500 $292.50, GHK-Cu $299.70, glutathione $238.50, NAD⁺ $267.30, MOTS-C $337.50, epithalon $233.10, PT-141 $260.10, kisspeptin $215.10, thymosin alpha-1 $231.30, testosterone $175.50 and enclomiphene $292.50. Those figures carry cents because they are the ten-percent subscription rate rather than the one-time price, which is a detail worth noticing: the headline you see is the auto-refill price, and stopping the subscription raises it. The bigger arithmetic point is the consult. A required telehealth visit at $49 is automatically added to the cart on purchase, and the site does not state whether that repeats on every auto-refill or applies only to the first order — treat it as per-order until you have it in writing, because on a $225 peptide a recurring $49 is a fifth again on top. Ask that question before your first order, not after your second charge.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. ElitePhysiqMD states its medications come from state-licensed 503A and 503B compounding pharmacies registered with FDA, which is a clearer sourcing description than most of this board offers, but it names no individual pharmacy — and compounded sterile products are not reviewed by FDA for purity and potency the way approved drugs are. On the evidence, a priced menu is only useful if you know the prices do not tell you which products work, and here they emphatically do not. Sermorelin, CJC-1295/ipamorelin and tesamorelin act on the growth-hormone axis, a real and well-described mechanism; tesamorelin is the one with genuine approved human evidence, and that evidence is for HIV-associated lipodystrophy specifically, not the body-composition and anti-aging outcomes the category is marketed on, and the compounded version sold here is not the approved product. For sermorelin and CJC-1295/ipamorelin, long-term human outcome data stays thin. BPC-157, GHK-Cu and injectable glutathione sit lower again, with essentially no controlled human outcome trials for the healing, skin and recovery claims attached to them. NAD⁺ by injection has no controlled outcome trials either; the studied forms are the oral precursors NR and NMN, which raise blood NAD⁺ rather than demonstrating a clinical benefit. PT-141 is the outlier in the other direction — bremelanotide has been through registrational human trials for hypoactive sexual desire disorder in premenopausal women. Individual results vary.

Pros and watch-outs

The evidence behind what ElitePhysiqMD prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• Ipamorelin & CJC-1295: the honest evidence on GH secretagogue peptides

  They reliably raise growth hormone — that part is real. The muscle, fat-loss and anti-aging claims are not supported by human outcome data. A straight read.

• Tesamorelin (Egrifta): what it's actually FDA-approved for, and the evidence

  A real, approved GHRH analog — for HIV-associated lipodystrophy specifically. What the pivotal trials showed, and why the longevity use is an extrapolation.

• BPC 157: what the evidence actually shows (and what it doesn't)

  The 'healing peptide' has a deep rodent literature and almost no human data. A straight read of where the science stands.

• GHK-Cu: the copper peptide between real skincare and overclaim

  A decades-deep molecule with a credible topical story — and systemic anti-aging claims that outrun the human data.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• PT-141 (bremelanotide): the evidence on a research-popular peptide that is actually FDA-approved

  Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.

• TRT: what testosterone therapy is actually proven to do

  An FDA-approved therapy for diagnosed hypogonadism — with real but moderate benefits (sexual function, mood; not vitality), cardiovascular non-inferiority in TRAVERSE, and a real fertility trade-off.

• Enclomiphene: the evidence for restoring testosterone without replacing it

  Randomized trials, including two Phase III RCTs, show enclomiphene restores a man's own testosterone while preserving fertility — but it was never FDA-approved.

How ElitePhysiqMD compares

A few alternatives worth a look, depending on what you’re optimizing for.

• CoreAge Rx

  Injected or intranasal NAD⁺ at a published price across 50 states

  See CoreAge Rx →
• SLSystem Labs

  NAD⁺ bundled with glutathione, B-12 and sermorelin from one service

  See System Labs →
• Invigor Medical

  Prescription at-home NAD⁺ injections via telehealth

  See Invigor Medical →